Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer
Convergent Science Physical Oncology · 2017
DOI: 10.1088/2057-1739/aa5cf1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Convergent Science Physical Oncology, 2017. Verfasst von Paula Cunnea und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Cancer, Imperial College London. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIBIB NIH HHS, Medical Research Council.
Abstract (Originalsprache)
Epithelial Ovarian cancer (EOC) is the fifth most common cause of cancer death in females in the UK. It has long been recognized to be a set of heterogeneous diseases, with high grade serous being the most common subtype. The majority of patients with EOC present at an advanced stage (FIGO III-IV), and have the largest risk for disease recurrence from which a high percentage will develop resistance to chemotherapy. Despite continual advances in diagnostics, imaging, surgery and treatment of EOC, there has been little variation in the survival rates for patients with EOC. In this review we will introduce novel bioengineering advances in modelling the lymphatic system and real-time tissue monitoring to improve the clinical and therapeutic outcome for patients with EOC. We discuss the advent of the non-invasive "liquid biopsy" in the surveillance of patients undergoing treatment and follow-up. Finally, we present new bioengineering advances for palliative care of patients to lessen symptoms of patients with ascites and improve quality of life.
Autor:innen und Institutionen
- Department of Surgery and Cancer, Imperial College London.
- Department of Bioengineering, Imperial College London.
Förderung
- NHLBI NIH HHS
- NIBIB NIH HHS
- Medical Research Council
Zitieren
APA
Cunnea, P., Gowers, S., Moore, J. E., Drakakis, E., Boutelle, M., & Fotopoulou, C. (2017). Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer. Convergent Science Physical Oncology. https://doi.org/10.1088/2057-1739/aa5cf1
Vancouver
Cunnea P, Gowers S, Moore JE, Drakakis E, Boutelle M, Fotopoulou C. Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer. Convergent Science Physical Oncology. 2017. doi:10.1088/2057-1739/aa5cf1
BibTeX
@article{Cunnea2017,
author = {Cunnea, Paula and Gowers, Sally and Moore, James E and Drakakis, Emmanuel and Boutelle, Martyn and Fotopoulou, Christina},
title = {Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer},
journal = {Convergent Science Physical Oncology},
year = {2017},
doi = {10.1088/2057-1739/aa5cf1}
}
EUVIMED